Clinical Trials Logo

Hemoglobinuria clinical trials

View clinical trials related to Hemoglobinuria.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06412497 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Start date: June 5, 2024
Phase: Phase 2
Study type: Interventional

A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.

NCT ID: NCT06298955 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Start date: February 19, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.

NCT ID: NCT06294301 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Start date: November 19, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-005 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT06238544 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: February 6, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included. All eligible subjects received HRS-5965 tablets until the end of treatment in this study.

NCT ID: NCT06154512 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Real-world, Multi-center, Prospective, Observational Study for PNH in China

ReWoPNH
Start date: November 10, 2023
Phase:
Study type: Observational [Patient Registry]

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

NCT ID: NCT06100900 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Start date: October 24, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in participants with paroxysmal nocturnal hemoglobinuria (PNH). Approximately 15 participants will be enrolled in this study. Participants may receive treatment for up to 24 weeks.

NCT ID: NCT06050226 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: July 6, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH , showing signs of active hemolysis, in China.

NCT ID: NCT05972967 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

Start date: March 27, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of OMS906 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients who have a sub-optimal response to ravulizumab.

NCT ID: NCT05889299 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: December 9, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

NCT ID: NCT05876312 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

PNH
Start date: July 3, 2023
Phase: Phase 1
Study type: Interventional

The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy volunteers (HV) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).